Navigation Links
EntreMed Enters into $7.5 Million Equity Facility and Initiates $1.1 Million Drawdown
Date:6/28/2011

targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase I clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound's applicability for other forms of cancer.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the SEC.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; our reliance on a single product candidate, ENMD-2076; the volatility of our common stock; our history of losses and expectation of incurring continued losses; risks relating to the need for additional capital and th
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
2. EntreMed Reports First Quarter 2011 Financial Results
3. EntreMed Reports Third Quarter 2010 Financial Results
4. EntreMed Receives Notice of NASDAQ Compliance
5. EntreMed Secures $5.1 Million in Registered Direct Offering and Enters into Agreement for Rights to License ENMD-2076 in China
6. EntreMed Receives NASDAQ Listing Rule 5550(b)(2) Determination Letter
7. EntreMed Reports Second Quarter 2010 Financial Results
8. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
9. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
10. EntreMed Presents Initial Clinical Results for ENMD-2076
11. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Conkwest, Inc., the Natural Killer Cell ... Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an ... , NantWorks founder, physician scientist and biotechnology entrepreneur, ... approximately $48 million of the Company,s Class A ... will be named Co-Chairman of the Conkwest Board ...
(Date:12/24/2014)... and LONDON , December 24, ... industry are expected to grow at an average rate ... of value and volume. Hip, knee and spine surgeries ... while in emerging economies they have a lower penetration. ... challenging the use of composites. Non-metallic orthopedic devices have ...
(Date:12/24/2014)... Wash. , Dec. 23, 2014  Advanced ... development company engaged primarily in the development of ... therapeutic applications, today announced that it has filed ... Food and Drug Administration ("FDA") for marketing clearance ... Section 513(f)(2) of the U.S. Food, Drug and ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... 2011 Reportlinker.com announces that a new ... catalogue: X-ray Equipment - ... http://www.reportlinker.com/p0683628/X-ray-Equipment---Top-5-American-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging This package ... the following American countries: United States, Mexico, ...
... Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company ... treatment of human viral diseases, today announced the pricing of ... common stock at a public offering price of $6.50 per ... The offering is expected to close on November 21, 2011, ...
Cached Medicine Technology:X-ray Equipment - Top 5 American Markets 2Idenix Pharmaceuticals Prices Public Offering of Common Stock 2
(Date:12/25/2014)... Aliso Viejo, California (PRWEB) December 25, 2014 ... the release of ProFire 5k. A fully customizable business ... X . , “Adding the ProFire 5k business tool, ... style” Said Christina Austin, CEO of Pixel Film Studios. ... the look and style to add professionalism to a ...
(Date:12/25/2014)... Rosa, CA (PRWEB) December 25, 2014 ... department visits and 2 million hospital admissions across the ... and Prevention ). The CDC’s National Hospital Ambulatory ... departments through a survey conducted in 2010. They estimated ... department visits that resulted in a primary diagnosis of ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in ... the holiday season, AlignLife looks forward to their annual toy ... Sara Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as ... are able to give kids toys for Christmas who would ... generosity of our patients." , The 70 toys were donated ...
(Date:12/24/2014)... December 25, 2014 Epigenetics finds applications ... research, including oncology, drug discovery, developmental biology, and research ... as one of the most widely used techniques for ... GLOBOCAN, the prevalence of cancer is rapidly growing worldwide. ... 8.2 million cancer deaths, and 32.6 million people living ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and retailer, ... . All these items are brand new; they are made ... updated with the new range of high quality prom gowns. ... iFitDress.com’s designs are made according to the latest trends. For ... outfit from the company is handpicked by skilled tailors. , ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... the University of Aberdeen in the UK say in a ... linked to increased risk of asthma in kids//. The study ... team showed that low vitamin E in mothers was linked ... ,In this study researchers followed 1,000 children at five years. ...
... village died after eating wild poisonous mushrooms while their mother ... Begma, 8, Neelma, 5, and Jaywanti, 2, died Friday in ... here. ,All the children fell unconscious and died ... 30, managed to survive but is still recovering from food ...
... improve donor lung quality as part of the San ... number of available donor lungs and transplant procedures without ... survival. ,The study appears in the second ... Respiratory and Critical Care Medicine, published by the American ...
... Carolina Wilmington announce the continuation of funding to study ... ultimately// yield treatments. The National Institute of Environmental Health ... to further delve into the acute and chronic effects ... Florida's west coast. ,"Preliminary studies with red ...
... in the Sun's brightness over the past millennium have ... to a review of existing results and new calculations// ... Germany. ,The review, led by Peter Foukal (Heliophysics, ... Among the coauthors is Tom Wigley of the National ...
... the inner lining of the nose are linked to ... current treatments according// to researchers at John Hopkins University. ... the misery of persistent inflammation of the moist tissue ... is clogged passages and recurring infections, according to the ...
Cached Medicine News:Health News:Upgrading Donor Lung Quality to Improve Availability 2Health News:Upgrading Donor Lung Quality to Improve Availability 3Health News:"Beach to Bedside" Study Focuses on Effects of Inhaled Toxins 2Health News:Changes in Solar Brightness Too Weak to Explain Global Warming 2Health News:Changes in Solar Brightness Too Weak to Explain Global Warming 3Health News:Chronic Sinusitis Resulting From Weakene Immune System 2Health News:Chronic Sinusitis Resulting From Weakene Immune System 3
100% Silicone Foley Catheter Kits 2-Way...
ULTRAMER Foley Catheter...
Foley Catheters (Latex) 2-Way...
Silicone Elastomer-Coated Latex Foley Catheters 3-Way...
Medicine Products: